Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma

Recruiting now

Conditions studied: Ewing Sarcoma

In brief

This single-center prospective observational study aims to evaluate whether longitudinal changes in serum pro-gastrin-releasing peptide (ProGRP) reflect treatment response in patients with newly diagnosed Ewing sarcoma. Serum ProGRP levels will be measured before systemic treatment, during neoadjuvant chemotherapy, before local treatment, and after local treatment. Changes in ProGRP will be compared with radiographic tumor response assessed according to RECIST version 1.1. The study will also explore the ability of early ProGRP changes to predict objective radiographic response and the association between ProGRP patterns and event-free survival. ProGRP results obtained for research purposes will not be used to guide clinical treatment decisions.

Key facts

Study ID

NCT07725783

Run by

Peking University People's Hospital

People needed

100

Starts

2025-09-01

Expected to finish

2026-09-01

Last updated by the study team

2026-07-24

Who can join

Age: 10 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 10 to 60 years.
• Histologically confirmed Ewing sarcoma.
• Newly diagnosed disease and scheduled to initiate first-line systemic therapy at Peking University People's Hospital.
• No prior systemic chemotherapy for Ewing sarcoma and no prior radiotherapy to the primary tumor.
• At least one evaluable lesion on baseline imaging; at least one measurable lesion according to RECIST version 1.1 is required for the primary outcome analysis.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• Estimated life expectancy greater than 3 months.
• Written informed consent provided by the participant or the participant's legally authorized representative.

You may not qualify if…

• History of another malignant tumor within the previous 3 years, except for an adequately treated malignancy with a negligible risk of recurrence, as determined by the investigator.
• New York Heart Association (NYHA) class III or IV heart failure.
• Uncontrolled concomitant illness, including uncontrolled diabetes mellitus or an active infection.
• Severe infection requiring intravenous antimicrobial treatment within 4 weeks before enrollment.
• Clinically significant bleeding or a clear bleeding tendency within 3 months before enrollment.
• Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m².
• Pregnancy or breastfeeding.
• Any condition that, in the investigator's judgment, may compromise participant safety, interfere with study assessments, or prevent compliance with the protocol.

Where it is running

• Peking University People's Hospital, Beijing, Beijing 100044 — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.